US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
WO2000035889A1
(en)
*
|
1998-12-11 |
2000-06-22 |
Sankyo Company, Limited |
Substituted benzylamines
|
TR200002099A3
(en)
|
1999-07-22 |
2001-06-21 |
Sankyo Company Limited |
Cyclobutene derivatives, their preparation and therapeutic uses
|
PT1218401E
(en)
*
|
1999-09-22 |
2004-10-29 |
Aventis Pharma Gmbh |
4-BENZYLAMINOQUINOLINS CONTAINED WITH BILIARY ACID AND ITS HETEROCYCLICS METHODS OF THEIR PRODUCTION MEDICINES CONTAINING THESE COMPOUNDS AND ITS APPLICATION
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
GB2431927B
(en)
|
2005-11-04 |
2010-03-17 |
Amira Pharmaceuticals Inc |
5-Lipoxygenase-activating protein (FLAP) inhibitors
|
US7977359B2
(en)
|
2005-11-04 |
2011-07-12 |
Amira Pharmaceuticals, Inc. |
5-lipdxygenase-activating protein (FLAP) inhibitors
|
US8399666B2
(en)
|
2005-11-04 |
2013-03-19 |
Panmira Pharmaceuticals, Llc |
5-lipoxygenase-activating protein (FLAP) inhibitors
|
WO2008061236A2
(en)
*
|
2006-11-16 |
2008-05-22 |
Allergan, Inc. |
Sulfoximines as kinase inhibitors
|
MX2010010773A
(en)
|
2008-04-01 |
2011-04-11 |
Abbott Gmbh & Co Kg |
Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy.
|
US20110160249A1
(en)
|
2008-05-23 |
2011-06-30 |
Schaab Kevin Murray |
5-lipoxygenase-activating protein inhibitor
|
AR075442A1
(en)
|
2009-02-16 |
2011-03-30 |
Abbott Gmbh & Co Kg |
AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
|
WO2011150286A2
(en)
|
2010-05-26 |
2011-12-01 |
Satiogen Pharmaceuticals,Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
US8846743B2
(en)
|
2010-08-13 |
2014-09-30 |
Abbott Laboratories |
Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US8877794B2
(en)
|
2010-08-13 |
2014-11-04 |
Abbott Laboratories |
Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US9051280B2
(en)
|
2010-08-13 |
2015-06-09 |
AbbVie Deutschland GmbH & Co. KG |
Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US8883839B2
(en)
|
2010-08-13 |
2014-11-11 |
Abbott Laboratories |
Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US9045459B2
(en)
|
2010-08-13 |
2015-06-02 |
AbbVie Deutschland GmbH & Co. KG |
Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
RS60901B1
(en)
|
2010-11-08 |
2020-11-30 |
Albireo Ab |
Ibat inhibitors for the treatment of liver diseases
|
US9309200B2
(en)
|
2011-05-12 |
2016-04-12 |
AbbVie Deutschland GmbH & Co. KG |
Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
TW201319049A
(en)
|
2011-08-05 |
2013-05-16 |
Abbott Gmbh & Co Kg |
Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
|
CN104023727B
(en)
|
2011-10-28 |
2017-04-05 |
鲁美纳医药公司 |
For treating the bile acid recycling inhibitors of children's cholestatic liver disease
|
CN104023718B
(en)
|
2011-10-28 |
2017-04-05 |
鲁美纳医药公司 |
For treating the bile acid recycling inhibitors of high cholemia and cholestatic liver disease
|
CA2853254A1
(en)
|
2011-11-18 |
2013-05-23 |
Abbvie Inc. |
N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US9365512B2
(en)
|
2012-02-13 |
2016-06-14 |
AbbVie Deutschland GmbH & Co. KG |
Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
|
AU2014228850A1
(en)
|
2013-03-15 |
2015-10-29 |
Lumena Pharmaceuticals Llc |
Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
|
US9656955B2
(en)
|
2013-03-15 |
2017-05-23 |
Abbvie Inc. |
Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US9650334B2
(en)
|
2013-03-15 |
2017-05-16 |
Abbvie Inc. |
Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
AU2014229050A1
(en)
|
2013-03-15 |
2015-10-22 |
Lumena Pharmaceuticals Llc |
Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
|
AU2014336154A1
(en)
|
2013-10-17 |
2016-04-28 |
AbbVie Deutschland GmbH & Co. KG |
Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
|
AU2014336153A1
(en)
|
2013-10-17 |
2016-04-28 |
AbbVie Deutschland GmbH & Co. KG |
Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
|
CA2952406A1
(en)
|
2014-06-25 |
2015-12-30 |
Ea Pharma Co., Ltd. |
Solid formulation and method for preventing or reducing coloration thereof
|
US10786529B2
(en)
|
2016-02-09 |
2020-09-29 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US10441605B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US10441604B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Cholestyramine pellets and methods for preparation thereof
|
CA3071285A1
(en)
|
2017-08-09 |
2019-02-14 |
Albireo Ab |
Cholestyramine granules, oral cholestyramine formulations and use thereof
|
JP7391048B2
(en)
|
2018-06-05 |
2023-12-04 |
アルビレオ・アクチボラグ |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
US10793534B2
(en)
|
2018-06-05 |
2020-10-06 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
CA3100691A1
(en)
|
2018-06-20 |
2019-12-26 |
Albireo Ab |
Crystal modifications of odevixibat
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US11549878B2
(en)
|
2018-08-09 |
2023-01-10 |
Albireo Ab |
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US10941127B2
(en)
|
2019-02-06 |
2021-03-09 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
US10975045B2
(en)
|
2019-02-06 |
2021-04-13 |
Aibireo AB |
Benzothiazepine compounds and their use as bile acid modulators
|
JP2022520121A
(en)
|
2019-02-12 |
2022-03-28 |
ミルム ファーマシューティカルズ インコーポレイテッド |
How to treat cholestasis
|
WO2021037759A1
(en)
|
2019-08-28 |
2021-03-04 |
Unilever Global Ip Limited |
Novel compounds for skin lightening
|
WO2021037750A1
(en)
|
2019-08-28 |
2021-03-04 |
Unilever Global Ip Limited |
Novel compounds for skin lightening
|
CN114786772B
(en)
|
2019-12-04 |
2024-04-09 |
阿尔比里奥公司 |
Benzothiazepine compounds and their use as bile acid modulators
|
JP2023504645A
(en)
|
2019-12-04 |
2023-02-06 |
アルビレオ・アクチボラグ |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
US11014898B1
(en)
|
2020-12-04 |
2021-05-25 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
CA3158181A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
EP4069247A1
(en)
|
2019-12-04 |
2022-10-12 |
Albireo AB |
Benzothiadiazepine compounds and their use as bile acid modulators
|
JP2023537285A
(en)
|
2020-08-03 |
2023-08-31 |
アルビレオ・アクチボラグ |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
EP4243831A1
(en)
|
2020-11-12 |
2023-09-20 |
Albireo AB |
Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
|
JP2024500309A
(en)
|
2020-12-04 |
2024-01-09 |
アルビレオ エービー |
Benzothia(di)azepine compounds and their use as bile acid modulators
|